Insiders · ALMS

Patrick Machado

Director at Alumis Inc. (ALMS)

Patrick Machado has filed 31 insider reports with the SEC since January 2021, as director at Alumis Inc. (ALMS), director at Arcus Biosciences, Inc. (RCUS) and director at Xenon Pharmaceuticals Inc. (XENE) and at 4 more companies. Patrick Machado made no open-market purchases or sales in the last 12 months. The latest filing, on July 2, 2026, reports grant or award at Alumis Inc. (ALMS).

Filings
31
Companies
7
Bought on market
$214K
Sold on market
None

Companies where Patrick Machado is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Alumis Inc. logo
ALMS
Alumis Inc.
Director3,553$4.395Jul 2, 2026
Arcus Biosciences, Inc. logo
RCUS
Arcus Biosciences, Inc.
Director44,300$15.76Jun 12, 2026
Xenon Pharmaceuticals Inc. logo
XENE
Xenon Pharmaceuticals Inc.
Director2,645$37.75Jun 4, 2026
Adverum Biotechnologies, Inc. logo
ADVM
Adverum Biotechnologies, Inc.
Director0$214K$10.72Dec 10, 2025
ACELYRIN, Inc. logo
SLRN
ACELYRIN, Inc.
DirectorMay 23, 2025
Chimerix Inc logo
CMRX
Chimerix Inc
DirectorJun 12, 2023
Turning Point Therapeutics, Inc. logo
TPTX
Turning Point Therapeutics, Inc.
DirectorAug 17, 2022

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Also sits on boards with

Officers and directors who share two or more companies with Patrick Machado.

Compare Patrick Machado with

Other insiders at the same companies

Questions about Patrick Machado

What is Patrick Machado's role at Alumis Inc.?
Patrick Machado reports to the SEC as director at Alumis Inc. (ALMS), according to the latest filing on July 2, 2026. Patrick Machado has also filed as director at Arcus Biosciences, Inc. (RCUS), director at Xenon Pharmaceuticals Inc. (XENE), director at Adverum Biotechnologies, Inc. (ADVM) and director at ACELYRIN, Inc. (SLRN).
How many shares does Patrick Machado own?
After the latest filing that states it, Patrick Machado directly owned 3,553 shares of Alumis Inc. (ALMS), 44,300 shares of Arcus Biosciences, Inc. (RCUS) and 2,645 shares of Xenon Pharmaceuticals Inc. (XENE). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Patrick Machado bought or sold stock recently?
The most recent open-market purchase was on March 24, 2021: bought 10,000 shares of Adverum Biotechnologies, Inc. (ADVM) for $99.2K at an average of $9.92.
How do I get alerts when Patrick Machado files?
Follow Patrick Machado on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Patrick Machado (SEC CIK 0001311210). Totals count each trade once, skipping amendments whose original is on file, from Jan 20, 2021 on. View on SEC EDGAR